Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumosa Therapeutics Co (ROCO:6535) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Lumosa Therapeutics Co Effective Interest Rate on Debt % Related Terms
Lumosa Therapeutics Co Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Lumosa Therapeutics Co's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co Effective Interest Rate on Debt % Chart
ROCO:6535 vs VRTX, REGN, RVMD: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 1.91% mean?
Lumosa Therapeutics Co (ROCO:6535) has a Effective Interest Rate on Debt % of 1.91% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Lumosa Therapeutics Co and its competitors.
Is Lumosa Therapeutics Co's Effective Interest Rate on Debt % too high?
Lumosa Therapeutics Co's current Effective Interest Rate on Debt % is 1.91%. Overall, Lumosa Therapeutics Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Effective Interest Rate on Debt % compare to VRTX and REGN?
Lumosa Therapeutics Co's Effective Interest Rate on Debt % of 1.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Lumosa Therapeutics Co and its competitors. Lumosa Therapeutics Co's current Effective Interest Rate on Debt % is 1.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$127.94, compared to a current price of NT$91.10 — trading 28.8% below its estimated fair value. The current Effective Interest Rate on Debt % is 1.91%. Lumosa Therapeutics Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Effective Interest Rate on Debt % is 1.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$91.10 is trading 28.8% below its estimated GF Value™ of NT$127.94.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
Effective Interest Rate on Debt %: 1.91%
GF Value™: NT$127.94 vs. price of NT$91.10 (28.8% below fair value)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
70GF Score
Get the complete analysis for ROCO:6535
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
